drugset / Trial / NCT00791570
Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy
Phase 1
Completed
17 enrolled
Osaka University
Human Genome Center, Institute of Medical Science, University of Tokyo · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and time to progression of HLA-A\*2402 or A\*0201 restricted epitope peptides VEGFR1 and VEGFR2 emulsified with Montanide ISA 51 in patients with Neovascular Maculopathy, including Age Related Macular Degeneration
Timeline
- Start
- 2008-10
- Primary completion
- 2012-04
- Completion
- 2012-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VEGFR1 | Peptide | 1 mg | Subcutaneous |
| Subject | VEGFR2 | Peptide | 1 mg | Subcutaneous |